Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,454 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,230 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05924672 | Efficacy of Ra-223 in PSMA PET Optimally Selected Patients | active not recruiting | Phase 2 | 2 | University of California, San FranciscoOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06059118 | Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2026 |
| clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04647526 | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment(SPLASH) | active not recruiting | Phase 3 | 455 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyINDUSTRY | 6 | Jan 13, 2026 | clinicaltrials |
| NCT05926102 | The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)(ProGRESS) | recruiting | N/A | 5,000 | VA Office of Research and DevelopmentFED | 1 | Jan 13, 2026 | clinicaltrials |
| NCT02454543 | Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases(g-RAMPP) | active not recruiting | N/A | 452 | Martini-Klinik am UKE GmbHOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04269512 | Role of Lymphnode Dissection in Men With Prostate Cancer Treated With Radical Prostatectomy(PREDICT) | active not recruiting | N/A | 3,650 | Martini-Klinik am UKE GmbHOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04271579 | Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)(ProsTone) | recruiting | N/A | 397 | Martini-Klinik am UKE GmbHOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06117059 | The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance(PRECISION) | recruiting | N/A | 100 | NHS LothianOTHER_GOV | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06353321 | Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1 | recruiting | — | 25 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07112612 | Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer | not yet recruiting | — | 50 | Anhui Medical UniversityOTHER | 0 | Jan 12, 2026 | clinicaltrials |
| NCT07129551 | Navigation, Outcomes and Quality-of-life in Prostate Cancer Patients Undergoing PSMA-targeted Surgery(NICE-PSMA) | recruiting | N/A | 102 | Martini-Klinik am UKE GmbHOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07181473 | A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 200 | Phrontline BiopharmaINDUSTRY | 2 | Jan 12, 2026 | clinicaltrials |
| NCT07334275 | Detection of Minimal Residual Disease Post-prostatectomy(MiRaDE) | recruiting | — | 50 | Radboud University Medical CenterOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04777071 | An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer | active not recruiting | Phase 2 | 141 | University of WashingtonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07112599 | Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis | recruiting | — | 2,000 | Anhui Medical UniversityOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05570994 | 177Lu-HTK03170 in mCRPC With PSMA Positive Disease | enrolling by invitation | Phase 1 / Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06660862 | Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer. | not yet recruiting | Phase 4 | 80 | University of ChicagoOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07282808 | Focal or Radical Therapy: a Lesion-based Molecular Evaluation in Prostate Cancer(FLAME-PC) | recruiting | N/A | 130 | Singapore General HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03474913 | Upright MRI for Prostate Cancer Screening | recruiting | — | 550 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05010200 | The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.(PGV-Prostate) | active not recruiting | Phase 1 | 27 | Ashutosh Kumar TewariOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06391034 | Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer | recruiting | Phase 2 | 161 | Robert Bok, MD, PhDOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06970119 | A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 55 | Yunhe Pharmaceutical (Tianjin) Co., LtdOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07324798 | Adaptive Radiotherapy for Genitourinary Cancers(SMART-B01) | recruiting | N/A | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03017794 | Evaluation of Neuroendocrine Differentiation as a Potential Mechanism of Tumor Recurrence Following Radiotherapy | active not recruiting | — | 118 | Mayo ClinicOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06866938 | Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer(ReaLuP) | recruiting | Phase 2 | 58 | Hospices Civils de LyonOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07311915 | Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study | not yet recruiting | N/A | 30 | Zhongda HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07319923 | Establishment and Promotion of an AI-Based Early Warning System for Prostate and Bladder Cancer Screening in the Male Community Population of Beijing | recruiting | — | 3,000 | Peking University First HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07306741 | Cognitive and Fusion Prostatic Biopsy(CTB-FTB) | recruiting | N/A | 80 | Menoufia UniversityOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06717295 | The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling(CCANED-CIPHER) | recruiting | — | 6,000 | Javier ToledoINDUSTRY | 3 | Jan 2, 2026 | clinicaltrials |
| NCT01643954 | Retrospective/Prospective Analysis of Surgical Outcomes of Robotic Prostatectomy at The James | active not recruiting | N/A | 1,531 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04763980 | Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer | recruiting | N/A | 72 | University of California, San FranciscoOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05746806 | Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy(HypoFocal SRT) | active not recruiting | N/A | 36 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06084338 | Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc | recruiting | Phase 2 | 60 | VA Office of Research and DevelopmentFED | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06531499 | A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study(RADIODOSE) | recruiting | Phase 1 | 106 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 31, 2025 | clinicaltrials |
| NCT02051218 | Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks | active not recruiting | Phase 3 | 1,380 | Swiss Cancer InstituteOTHER | 3 | Dec 30, 2025 | clinicaltrials |
| NCT03383016 | Diet, Physical Activity and Related Candidate Biomarkers in Relation to Prostate Cancer Risk (BIOCaPPE)(BIOCaPPE) | active not recruiting | — | 2,053 | CHU de Quebec-Universite LavalOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT03809000 | A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery(STEEL) | active not recruiting | Phase 2 | 188 | RTOG Foundation, Inc.OTHER | 2 | Dec 30, 2025 | clinicaltrials |
| NCT07310355 | 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 49 | Chengdu StarRay Therapeutics Co., LtdINDUSTRY | 0 | Dec 30, 2025 | clinicaltrials |
| NCT07310433 | Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer | not yet recruiting | Phase 2 | 60 | Yung NAOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05519878 | Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers | recruiting | N/A | 224 | City of Hope Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07292337 | AcuTENS for Pain Relief During TRUS-Guided Prostate Biopsy | active not recruiting | N/A | 53 | University of MalayaOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07300566 | Focal Versus Whole Gland High Dose-Rate Brachytherapy (HDR-BT) Boost to External Beam Radiotherapy in Localized Prostate Cancer: A Phase 2 Randomized Trial(FORWARD) | not yet recruiting | Phase 2 | 58 | Joelle HelouOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07302763 | Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer Heterogeneity(4TMPO) | recruiting | N/A | 45 | Frederic PouliotOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT03492424 | Ablative Therapy in the Management of Prostate Cancer | recruiting | — | 200 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04655365 | Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.(PROSTEP-002) | active not recruiting | Phase 2 | 50 | CHU de Quebec-Universite LavalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06822491 | Early Magnetic Resonance Imaging Response of the Dominant Intraprostatic Lesion After Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer and Correlation With Prostate Specific Antigen Response(PRODART) | active not recruiting | — | 28 | University of ZurichOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07299292 | Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2) | recruiting | Phase 2 | 60 | SMED Clinical ResearchOTHER | 2 | Dec 23, 2025 | clinicaltrials |
| NCT06155084 | A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients | recruiting | Phase 1 / Phase 2 | 84 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jan 14, 2026source: clinicaltrials